Terapevt Arkh
-
Historical Article
[Anniversary of Academician of the Russian Academy of Sciences, Professor Alexander G. Chuchalin].
Alexander Grigorievich Chuchalin is a world-famous scientist, an outstanding representative of modern Russian medical science and practical health care, the founder of a whole area in Russian medicine - pulmonology. Thanks to his activities, his unique developments in Russia and abroad, millions of people with lung diseases have been saved. The whole domestic and world medical community congratulates Alexander Grigoryevich on his eightieth birthday!
-
The Universal Declaration on Bioethics and Human Rights was adopted at the UNESCO General Conference on October 19, 2005. From today's perspective, it must be recognized that it was adopted at a historically important period in the development of civilization; It has always been seen as a document that significantly expanded the declaration on human rights, as it gave a new interpretation of human activity in modern society. ⋯ Under the influence of these processes, our ideas about moral values and ethical principles changed. An idea of bioethics has formed; The term implies versatile human activities, including not only the doctor-patient relationship, but also the active participation of a person in the field of industry, climate change, as well as new areas such as editing the human genome, transplantology and much more.
-
Chronic obstructive pulmonary disease (COPD) is a group of diseases with high levels of comorbidity. Pathological changes of peripheral skeletal and respiratory muscles in COPD patients, which are often underestimated, occupy a special place.
-
The article presents modern data on the causes of platypnea, methods of its diagnosis and treatment. The data on the development of platypnea syndrome are given not only in cardiac pathology, but also in severe liver diseases with the development of hepatopulmonary syndrome and chronic obstructive pulmonary disease of a severe course.
-
Vedolizumab is currently the only selective biological drug for the treatment of inflammatory bowel diseases (IBD). Its effectiveness and safety has been shown in clinical trials. This article presents the experience of using vedolizumab in real clinical practice in patients with various forms of ulcerative colitis (UC) and Crohns disease (CD).